IMO having and gaining more distributors / countries is a double edge sword . The company seems to be trying to put pressure on the FDA with all the approvals for sale in all these contries , a good thing . The failure to show sales of any substancial amounts in these countries is a bad thing . The Canadian debacle is probabely their worst effort coupled with the UK and the rest of them . By not showing a clear demand for the product they weaken their case . The more they add and the less they show ( sales ) works in the FDA's favor . All efforts should have been put into the Canadian project as they are our closest neighbor . Instead of waiting for "shelf space" they should have created their own in any shape or form , Kiosks , store front rental mixed with other with other products . They're running this company like a service business instead of a "sales" business . In any "sales" business "product awareness" is paramont , if people can't see it , how will they buy it ? Look at all the other products out there they all have some type of "brick and mortar" approach . BIEL's dependence on these distributors who are earnings generated if the product doesn't take off , they let it sit there . Like I said they chose to put the cart before the horse . There is a point where management needs to wake up and realize all the potential of its products thAT they let go down the drain along with investors money . CAN THIS WHOLE MESS BE TURNED AROUND , ANSWER , YES , EASILY . JMHO .
GLTY
News 
Market Data 
Discover 
AI
